Actinium Pharmaceuticals (NYSE:ATNM) Receives “Buy” Rating from HC Wainwright

Actinium Pharmaceuticals (NYSE:ATNM)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $4.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 158.90% from the company’s current price.

Separately, StockNews.com raised Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, April 18th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Actinium Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $4.00.

Actinium Pharmaceuticals Stock Performance

NYSE:ATNM traded up $0.07 during trading hours on Monday, reaching $1.55. The stock had a trading volume of 97,514 shares, compared to its average volume of 504,099. Actinium Pharmaceuticals has a 52 week low of $1.03 and a 52 week high of $10.24. The company has a 50 day moving average price of $1.35 and a two-hundred day moving average price of $1.35. The stock has a market capitalization of $48.20 million, a PE ratio of -1.11 and a beta of -0.24.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Northern Trust Corp increased its stake in Actinium Pharmaceuticals by 4.9% in the fourth quarter. Northern Trust Corp now owns 251,930 shares of the company’s stock worth $317,000 after purchasing an additional 11,812 shares during the period. Creative Financial Designs Inc. ADV increased its stake in Actinium Pharmaceuticals by 16.1% in the first quarter. Creative Financial Designs Inc. ADV now owns 105,631 shares of the company’s stock worth $170,000 after purchasing an additional 14,624 shares during the period. AM Investment Strategies LLC increased its stake in Actinium Pharmaceuticals by 114.1% in the first quarter. AM Investment Strategies LLC now owns 30,872 shares of the company’s stock worth $50,000 after purchasing an additional 16,450 shares during the period. Vontobel Holding Ltd. purchased a new stake in Actinium Pharmaceuticals in the fourth quarter worth $32,000. Finally, Charles Schwab Investment Management Inc. increased its stake in Actinium Pharmaceuticals by 35.4% in the first quarter. Charles Schwab Investment Management Inc. now owns 97,604 shares of the company’s stock worth $157,000 after purchasing an additional 25,511 shares during the period. Institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).